ATH 33.3% 0.4¢ alterity therapeutics limited

Maybe we should give up on PBT2 and start selling that PLACEBOWe...

  1. 1,300 Posts.
    lightbulb Created with Sketch. 6
    Maybe we should give up on PBT2 and start selling that PLACEBO

    We have a drug that

    arrests brain volume reduction

    Improves cognition in HD and AD

    Alters CSF aBeta

    and needs to be studied at higher doses to show statistical significance

    Still the most promising treatment if the higher dose is safe

    Frustrating nonetheless and company needs to show the full data to allow us to understand what happened and update extension study which is obviously still going






 
watchlist Created with Sketch. Add ATH (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.